Cargando…

Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines

BACKGROUND: Type I Diabetes mellitus (T1D) is characterized by a specific destruction of β-cells by the immune system. During this process pro-inflammatory cytokines are released in the pancreatic islets and contribute for β-cells demise. Cytokine-induced iNOS activation, via NF-κB, is implicated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, V. R., Paula, C. C., Taniguchi, S., Ortis, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045109/
https://www.ncbi.nlm.nih.gov/pubmed/36977992
http://dx.doi.org/10.1186/s12860-023-00476-3
_version_ 1784913518908145664
author Oliveira, V. R.
Paula, C. C.
Taniguchi, S.
Ortis, F.
author_facet Oliveira, V. R.
Paula, C. C.
Taniguchi, S.
Ortis, F.
author_sort Oliveira, V. R.
collection PubMed
description BACKGROUND: Type I Diabetes mellitus (T1D) is characterized by a specific destruction of β-cells by the immune system. During this process pro-inflammatory cytokines are released in the pancreatic islets and contribute for β-cells demise. Cytokine-induced iNOS activation, via NF-κB, is implicated in induction of β-cells death, which includes ER stress activation. Physical exercise has been used as an adjunct for better glycemic control in patients with T1D, since it is able to increase glucose uptake independent of insulin. Recently, it was observed that the release of IL-6 by skeletal muscle, during physical exercise, could prevent β-cells death induced by pro-inflammatory cytokines. However, the molecular mechanisms involved in this beneficial effect on β-cells are not yet completely elucidated. Our aim was to evaluate the effect of IL-6 on β-cells exposed to pro-inflammatory cytokines. RESULTS: Pre-treatment with IL-6 sensitized INS-1E cells to cytokine-induced cell death, increasing cytokine-induced iNOS and Caspase-3 expression. Under these conditions, however, there was a decrease in cytokines-induced p-eIF2-α but not p-IRE1expression, proteins related to ER stress. To address if this prevention of adequate UPR response is involved in the increase in β-cells death markers induced by IL-6 pre-treatment, we used a chemical chaperone (TUDCA), which improves ER folding capacity. Use of TUDCA increased cytokines-induced Caspase-3 expression and Bax/Bcl-2 ratio in the presence of IL-6 pre-treatment. However, there is no modulation of p-eIF2-α expression by TUDCA in this condition, with increase of CHOP expression. CONCLUSION: Treatment with IL-6 alone is not beneficial for β-cells, leading to increased cell death markers and impaired UPR activation. In addition, TUDCA has not been able to restore ER homeostasis or improve β-cells viability under this condition, suggesting that other mechanisms may be involved. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12860-023-00476-3.
format Online
Article
Text
id pubmed-10045109
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100451092023-03-29 Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines Oliveira, V. R. Paula, C. C. Taniguchi, S. Ortis, F. BMC Mol Cell Biol Research BACKGROUND: Type I Diabetes mellitus (T1D) is characterized by a specific destruction of β-cells by the immune system. During this process pro-inflammatory cytokines are released in the pancreatic islets and contribute for β-cells demise. Cytokine-induced iNOS activation, via NF-κB, is implicated in induction of β-cells death, which includes ER stress activation. Physical exercise has been used as an adjunct for better glycemic control in patients with T1D, since it is able to increase glucose uptake independent of insulin. Recently, it was observed that the release of IL-6 by skeletal muscle, during physical exercise, could prevent β-cells death induced by pro-inflammatory cytokines. However, the molecular mechanisms involved in this beneficial effect on β-cells are not yet completely elucidated. Our aim was to evaluate the effect of IL-6 on β-cells exposed to pro-inflammatory cytokines. RESULTS: Pre-treatment with IL-6 sensitized INS-1E cells to cytokine-induced cell death, increasing cytokine-induced iNOS and Caspase-3 expression. Under these conditions, however, there was a decrease in cytokines-induced p-eIF2-α but not p-IRE1expression, proteins related to ER stress. To address if this prevention of adequate UPR response is involved in the increase in β-cells death markers induced by IL-6 pre-treatment, we used a chemical chaperone (TUDCA), which improves ER folding capacity. Use of TUDCA increased cytokines-induced Caspase-3 expression and Bax/Bcl-2 ratio in the presence of IL-6 pre-treatment. However, there is no modulation of p-eIF2-α expression by TUDCA in this condition, with increase of CHOP expression. CONCLUSION: Treatment with IL-6 alone is not beneficial for β-cells, leading to increased cell death markers and impaired UPR activation. In addition, TUDCA has not been able to restore ER homeostasis or improve β-cells viability under this condition, suggesting that other mechanisms may be involved. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12860-023-00476-3. BioMed Central 2023-03-28 /pmc/articles/PMC10045109/ /pubmed/36977992 http://dx.doi.org/10.1186/s12860-023-00476-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oliveira, V. R.
Paula, C. C.
Taniguchi, S.
Ortis, F.
Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title_full Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title_fullStr Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title_full_unstemmed Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title_short Pre-treatment with IL-6 potentiates β-cell death induced by pro-inflammatory cytokines
title_sort pre-treatment with il-6 potentiates β-cell death induced by pro-inflammatory cytokines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045109/
https://www.ncbi.nlm.nih.gov/pubmed/36977992
http://dx.doi.org/10.1186/s12860-023-00476-3
work_keys_str_mv AT oliveiravr pretreatmentwithil6potentiatesbcelldeathinducedbyproinflammatorycytokines
AT paulacc pretreatmentwithil6potentiatesbcelldeathinducedbyproinflammatorycytokines
AT taniguchis pretreatmentwithil6potentiatesbcelldeathinducedbyproinflammatorycytokines
AT ortisf pretreatmentwithil6potentiatesbcelldeathinducedbyproinflammatorycytokines